Key clinical point: Elderly patients with non-Hodgkin lymphoma are more likely to die, but not relapse, within 1 year of allogeneic hematopoietic cell transplantation.
Major finding: One-year nonrelapse mortality (NRM) was 13% for young patients, 20% for middle-age patients, and 33% for elderly patients (P less than .001).
Study details: A retrospective analysis of 3,919 patients with NHL who underwent alloHCT between 2003 and 2013.
Disclosures: The researchers reported having no financial disclosures.
Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025
This Week's Must Reads
Must Reads in Aggressive Lymphomas
Researchers characterize new subtype of high-grade DLBCL, 3 articles from the Journal of Clinical Oncology
Patient perspectives on NHL treatment, Chircop D et al. Eur J Oncol Nurs. 2018 Aug;35:117-21
Corticosteroid use poses risk of febrile neutropenia, Chao CR et al. J Natl Compr Canc Netw. 2018;16(10):1201-8
5F9 plus rituximab looks durable in NHL, Advani R et al. N Engl J Med. 2018;379:1711-21
Age is an independent predictor of mortality after transplant, Kyriakou C et al. Biol Blood Marrow Transplant. 2018 Sep 13. doi: 10.1016/j.bbmt.2018.08.025